StreetInsider.com News Articles

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Mon, 27 Jul 2026 14:23:00 -0400

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7

Orion Group Holdings to Report Second Quarter 2026 Financial Results on Tuesday, July 28, 2026

Tue, 14 Jul 2026 16:05:00 -0400

Conference Call to be held Wednesday, July 29, 2026, at 8:00 a.m. Central Time
HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN), a leading specialty construction company, today announced that it will issue its second quarter 2026 financial results after the close of the stock market on Tuesday, July 28, 2026.

A conference call and audio webcast with analysts and investors will be held the next day, Wednesday, July 29, 2026, at 9:00 a.m. Eastern Time/8:00 a.m. Central Time to discuss the results.

Live conference call: 844-481-2994
Live and archived

Orion Group Holdings to Report Second Quarter 2026 Financial Results on Tuesday, July 28, 2026

Tue, 14 Jul 2026 16:05:00 -0400

Conference Call to be held Wednesday, July 29, 2026, at 8:00 a.m. Central Time
HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN), a leading specialty construction company, today announced that it will issue its second quarter 2026 financial results after the close of the stock market on Tuesday, July 28, 2026.

A conference call and audio webcast with analysts and investors will be held the next day, Wednesday, July 29, 2026, at 9:00 a.m. Eastern Time/8:00 a.m. Central Time to discuss the results.

Live conference call: 844-481-2994
Live and archived

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The